{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:24:03Z","timestamp":1791415443360,"version":"4.3.3"},"reference-count":65,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Human rhinovirus (HRV) is the predominant cause of the common cold, but more importantly, infection may have serious repercussions in asthmatics and chronic obstructive pulmonary disorder (COPD) patients. A cell-based antiviral screen against HRV was performed with a subset of our proprietary compound collection, and an aminothiazole series with pan-HRV species and enteroviral activity was identified. The series was found to act at the level of replication in the HRV infectious cycle.\n                    <jats:italic>In vitro<\/jats:italic>\n                    selection and sequencing of aminothiazole series-resistant HRV variants revealed a single-nucleotide mutation leading to the amino acid change I42V in the essential HRV 3A protein. This same mutation has been previously implicated in resistance to enviroxime, a former clinical-stage antipicornavirus agent. Enviroxime-like compounds have recently been shown to target the lipid kinase phosphatidylinositol 4-kinase III beta (PI4KIII\u03b2). A good correlation between PI4KIII\u03b2 activity and HRV antiviral potency was found when analyzing the data over 80 compounds of the aminothiazole series, covering a 750-fold potency range. The mechanism of action through PI4KIII\u03b2 inhibition was further demonstrated by small interfering RNA (siRNA) knockdown of PI4KB, which reduced HRV replication and also increased the potency of the PI4KIII\u03b2 inhibitors. Inhibitors from two different structural classes with promising pharmacokinetic profiles and with very good selectivity for PI4KIII\u03b2 were used to dissociate compound-related toxicity from target-related toxicity. Mortality was seen in all dosing groups of mice treated with either compound, therefore suggesting that short-term inhibition of PI4KIII\u03b2 is deleterious.\n                  <\/jats:p>","DOI":"10.1128\/aac.00303-13","type":"journal-article","created":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T23:58:33Z","timestamp":1367884713000},"page":"3358-3368","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":85,"title":["Phosphatidylinositol 4-Kinase III Beta Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal Phenotype\n                    <i>In Vivo<\/i>"],"prefix":"10.1128","volume":"57","author":[{"given":"Catherine","family":"Spickler","sequence":"first","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lippens","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Kristine","family":"Laberge","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Desmeules","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9dith","family":"Bellavance","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Garneau","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Guo","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hucke","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Leyssen","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric H.","family":"Vaillancourt","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"D\u00e9cor","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"O'Meara","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Franti","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim (Canada) Ltd., Laval, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.023994-0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6989.1225"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.01.059"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.22.2453"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.9.2105011"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804181105"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0833OC"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152609787847695"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2267-2275.2005"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2444"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01123-12"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.6.892"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92520-4"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.1.102"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02249-10"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.290"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/375069"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4492-4499.2005"},{"key":"e_1_3_2_20_2","unstructured":"Biota Holdings Limited. 28 March 2012. HRV phase IIb study achieves primary endpoint. Biota Holdings Limited Notting Hill Victoria Australia. http:\/\/www.biota.com.au\/uploaded\/154\/1021819_20hrvphaseiibstudyachieve.pdf."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/ml2002955"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01254-07"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001847"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.11.002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2358"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02094-12"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006355"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir634"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092410"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.10.007"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.04.016"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201202-0330OC"},{"key":"e_1_3_2_33_2","first-page":"493","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed LJ","year":"1938","unstructured":"ReedLJ MuenchH. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493\u2013497.","journal-title":"Am. J. Hyg"},{"key":"e_1_3_2_34_2","volume-title":"Guide to the care and use of experimental animals","author":"Canadian Council of Animal Care","year":"1993","unstructured":"Canadian Council of Animal Care. 1993. Guide to the care and use of experimental animals, vol 1, 2nd ed. Canadian Council of Animal Care, Ottawa, Ontario, Canada.","edition":"2"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00934-08"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01739-07"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.3.1941-1952.1996"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.100"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00905-07"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01320-12"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.7.4189-4197.1995"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.7.4854-4857.1996"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.050"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.03.035"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2012.03.004"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.07.034"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06778-11"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.429"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.02.039"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02418-08"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902693106"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00059-11"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024970"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.312561"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2006.05.003"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/12993"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604935200"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8248783"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.341"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.012096-0"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2012.129"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/13770"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/1682"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012981"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00946-12"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.04.077"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00303-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00303-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:32:48Z","timestamp":1645464768000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00303-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1128\/AAC.00303-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.00303-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"2013-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}